Navigation Links
Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
Date:7/12/2010

rd to continuing to expand our development pipeline in the coming months and years, as we execute this dual-tracked development strategy to take advantage of the strength and breadth of the Staccato technology platform."

About AZ-007 (Staccato zaleplon)

Alexza is developing AZ-007 (Staccato zaleplon) for the treatment of insomnia in patients who have difficulty falling asleep, including those patients who awake in the middle of the night and have difficulty falling back asleep.  Zaleplon, a non-benzodiazepine hypnotic currently approved to treat insomnia, has a pharmacokinetic half-life of about one hour and is generally well tolerated in patients.

"We have combined the technology attributes of our Staccato system with the known pharmacology of zaleplon, in order to develop a product candidate with a specific profile for middle of the night insomnia.  When patients wake up in the middle of the night, they need a rapidly-acting drug with a short half-life to assist them in the return to sleep and to minimize residual or next-day effects," said James V. Cassella, PhD, Alexza Senior Vice President, R&D.  "With AZ-007, we expect to see a rapid and predictable onset of therapeutic action resulting from Staccato administration, and a short-lived duration of action resulting from the pharmacological half-life of zaleplon."

Middle-of-the-night insomnia (MOTN) is insomnia characterized by difficulty returning to sleep after awakening either in the middle of the night, or too early in the morning.  It has been reported that waking up in the middle of the night is the most frequently reported insomnia symptom, with one large study finding that approximately 35% of Americans over 18 reported waking up three or m
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
2. Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
3. Alexza Pharmaceuticals to Present at The Ninth Annual JMP Securities Research Conference
4. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
5. Alexza Pharmaceuticals Files Shelf Registration Statement
6. Alexza to Announce 2010 First Quarter Financial Results on Monday, May 10, 2010
7. Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
8. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
9. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
10. Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010
11. Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 PuraMed BioScience®, Inc., (OTC Pink: ... medicinal and healthcare products, announced it received the initial ... hemp-based, advanced headache relief product, for planned distribution to ... Colorado , Washington State , ... the MigraPure H Advanced headache relief gel formulation completed, ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
(Date:12/24/2014)... Calif. , Dec. 23, 2014 In response ... Doctors, Association of Sierra Leone , Direct ... Leone for the treatment of local health workers ... While a new dedicated Ebola care center was constructed for ... the facility is not available for local Sierra Leonean health ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... RAD001 reduces risk of disease progression by 70%, - RAD001 is first and ... Nexavar(R),** with potential to address ... unmet medical need,- Once-daily oral RAD001 directly targets ... and blood vessel growth, - RAD001 is currently being studied in multiple types ...
... Adding Singulair to Advair Offers no Additional ... Improvement in Overall Asthma ... 18 /PRNewswire-FirstCall/,-- Patients with both asthma and allergic rhinitis, ... with Advair,Diskus(R) (fluticasone propionate and salmeterol inhalation powder) as,compared ...
Cached Medicine Technology:RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 2RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 3RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 4RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 5RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 6Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM) 2Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM) 3
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses and ... of black one-shoulder cocktail dresses . In addition, all ... at discounted prices, up to 70% off. , ... weeks only. You know, we have thousands of frequent callers ... new items can visit our website for more details. The ...
(Date:12/25/2014)... 25, 2014 BambooFlooringChina.com sells many bamboo ... bamboo flooring. Today, the company announces big discounts ... styles and colors. , BambooFlooringChina.com is the world’s leader ... promotion is valid until Jan. 20, 2015. , The ... woven with a natural thread. All the bamboo strips ...
(Date:12/25/2014)... By Dennis Thompson ... -- Very sick children with complex chronic illnesses can receive ... a "medical home," with easy access to a team of ... were less likely to become seriously ill and need either ... received treatment at an enhanced medical home clinic at the ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... closing in on a "fountain of youth" drug that can ... older adults, a new study suggests. Seniors received a ... that targets a genetic signaling pathway linked to aging and ... The experimental medication, a version of the drug ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios have ... business presentation tool made specifically for Final Cut ... tool, users can now display their stats and facts ... Studios. “ProFire 5k gives users a multiple options to ... a presentation” , Pixel Film Studios takes the heat ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... YORK, Feb 26 Our faces are our calling ... and are connected with three out of the five ... what happens when what you see in the mirror ... News Release, go to: http://www.prnewswire.com/mnr/aafprs/35820/ If you have ...
... 26 Solos Endoscopy, Inc. (Pink Sheets: SNDY) is ... significant purchase order for the MammoView(TM) line of surgical ... Waterbury Hospital, the cornerstone of the Greater Waterbury Health ... care services since 1983 and is accredited by the ...
... Pharma, Inc.,(Nasdaq: IDMI ) today announced that ... and more than 100 patient organizations, caregivers,researchers and companies ... on February 28. The goal of the day ... by those affected and the importance,of research to develop ...
... (Nasdaq: STRM ) announced today that Jay ... of Directors. The addition of Mr. Miller brings to ... Health Board of Directors.Mr. Miller has spent roughly 25 ... development; sales and marketing; and profit and loss responsibilities. ...
... - Quarter Highlighted by Regulatory Approval of Once-Daily Tramadol in, ... for Novel Treatment for Depression -,LAVAL, QC, Feb. 26 /PRNewswire-FirstCall/ ... today reported its results for the fourth quarter and year ... unless otherwise stated. , "With our first product about to ...
... To Autism" and Provides Important Information on Early ... Toys"R"Us and Babies"R"Us stores nationwide will kick off ... Speaks, the nation,s leading organization dedicated to increasing ... the causes, prevention and treatments for autism; and ...
Cached Medicine News:Health News:Video: Facing the Facts - What You Need to Know About Facial Plastic Surgery 2Health News:Solos Endoscopy, Inc. Receives Purchase Order from Major Connecticut Hospital for the MammoView(TM) 2Health News:IDM Pharma Joins NORD to Raise Awareness of Rare Diseases 2Health News:IDM Pharma Joins NORD to Raise Awareness of Rare Diseases 3Health News:IDM Pharma Joins NORD to Raise Awareness of Rare Diseases 4Health News:Streamline Health Appoints Jay D. Miller to Board of Directors 2Health News:Streamline Health Appoints Jay D. Miller to Board of Directors 3Health News:Streamline Health Appoints Jay D. Miller to Board of Directors 4Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 2Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 3Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 4Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 5Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 6Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 7Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 8Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 9Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 10Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 11Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 12Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 13Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 14Health News:Toys'R'Us and Babies'R'Us Launch In-Store Fundraising Campaign to Benefit Autism Speaks 2Health News:Toys'R'Us and Babies'R'Us Launch In-Store Fundraising Campaign to Benefit Autism Speaks 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: